MorphineNCT07842861
Morphine Versus Dexmedetomidine as Adjuvants to Bupivacaine in TAP Block in Lower Abdominal Surgeries
A study testing Transversus abdominis plane block + Dexmedetomidine and Morphine in people with Morphine and Dexmedetomidine, run by Cairo University at 1 site in Egypt.
Trial summary
This study aimed to ascertain the safety and efficacy of dexmedetomidine in comparison to morphine as adjuvants to bupivacaine during transversus abdominis plane (TAP) block in postoperative pain management in adult patients undergoing lower abdominal surgery. Read more about this study
- Who is it for?
- Ages 18 to 60 years
- Conditions the study is for
- Morphine, Dexmedetomidine, Adjuvants
- What is being tested?
- Transversus abdominis plane block + Dexmedetomidine and Morphine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 70 participants
- Where
- 1 siteEgypt
- Study dates
- 1 Dec 2025to 1 Jun 2026
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 60 years
- All sexes
- No healthy volunteers
- Adult
Who may be able to join
- Age from 18 to 60 years.
- Both genders.
- Classified according to the American Society of Anesthesiologists physical status (ASA) classification system as I-II.
- Body mass index (BMI) of less than 30.
- Patients scheduled to undergo elective surgical procedures on the lower abdominal region.
Who cannot join
- Patients with hypersensitivity to the utilized pharmaceutical agents.
- Mental disorders.
- Serious pulmonary or cardiac disease.
- Severe renal insufficiency.
- Coagulopathy.
- Infection at the injection site.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Comparative Study Between Morphine and Dexmedetomidine as Adjuvants to Bupivacaine in TAP Block in Lower Abdominal Surgeries: A Randomized Double-Blinded Clinical Study
This study aimed to ascertain the safety and efficacy of dexmedetomidine in comparison to morphine as adjuvants to bupivacaine during transversus abdominis plane (TAP) block in postoperative pain management in adult patients undergoing lower abdominal surgery.
Read the detailed description
Postoperative pain is a significant contributor to higher morbidity, patient discomfort, and extended hospital stays.
The ultrasound-guided transversus abdominis plane (TAP) block has become more popular than systemic analgesics for reducing pain following abdominal surgery.
A plethora of adjuvants, including but not limited to morphine, fentanyl, and dexmedetomidine, have been incorporated into various regimens of TAP block, yielding disparate outcomes.
The use of alpha-2 agonist dexmedetomidine has been sanctioned for its application as an adjuvant in the management of pain and as a venous sedative.
- Conditions
- Morphine, Dexmedetomidine, Adjuvants, Bupivacaine, Transversus Abdominis Plane Block, Lower Abdominal Surgeries
- Being tested
- Transversus abdominis plane block + Dexmedetomidine, Morphine
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Transversus abdominis plane block + DexmedetomidineDrug
Patients received transversus abdominis plane (TAP) block with bupivacaine 0.25% plus a dose of 1 µg/kg of dexmedetomidine.
MorphineDrug
Patients received a dose of 10 mg of morphine.
| Study group | Role | What they receive |
|---|---|---|
| Group D | Experimental | Patients received transversus abdominis plane (TAP) block with bupivacaine 0.25% plus a dose of 1 µg/kg of dexmedetomidine. Receives: Drug: Transversus abdominis plane block + Dexmedetomidine |
| Group M | Experimental | Patients received a dose of 10 mg of morphine. Receives: Drug: Morphine |
What is being measured
The primary outcome is the main question the study is designed to answer.
Duration of analgesia
Duration of analgesia was defined as the time interval from the end of the surgical procedure to the administration of the initial dose of morphine.
Measured: 24 hours postoperatively
Secondary outcomes (4)
Total opioid dose required
The total morphine consumption in the initial 24 hours following the surgical procedure was recorded.
Measured: 24 hours postoperatively
Degree of pain
Degree of pain was was conducted using the Visual Analog Scale (VAS) for each patient. The numerical value assigned to each category on the VAS scale is as follows: 0 represents "no pain," while 10 represents "the worst pain imaginable." In the post-anesthesia care unit, the VAS was assessed at 0, 2, 4, 6, 8, 12, and 24 hours after surgery.
Measured: 24 hours postoperatively
Incidence of adverse events
Incidence of adverse events such as bradycardia, hypotension, respiratory depression, and postoperative nausea and vomiting (PONV) were recorded.
Measured: 24 hours postoperatively
Degree of patient satisfaction
The degree of patient satisfaction was assessed using a 5-point Likert scale, ranging from 1 (extremely dissatisfied) to 5 (extremely satisfied).
Measured: 24 hours postoperatively
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted25 Sep 2026
- Study start1 Dec 2025
- Primary completion1 Jun 2026
- Study completion1 Jun 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for MorphineStudies of the same condition, open and under way.
- More trials run by Cairo UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Outcomes assessor
- Enrolment
- 70 participants (actual)
Sponsor and investigators
- Lead sponsor
- Cairo University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Heba Mahmoud Raafat, Cairo University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07842861
- Sponsor's protocol ID
- MS-660-2025
- Status last verified
- Sep 2026
- First submitted
- 21 Sep 2026
- Last updated
- 25 Sep 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: The data will be available upon a reasonable request from the corresponding author after the end of study for one year.
Study at a glance
From the registry record, last updated by the sponsor on 25 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Comparative Study Between Morphine and Dexmedetomidine as Adjuvants to Bupivacaine in TAP Block in Lower Abdominal Surgeries: A Randomized Double-Blinded Clinical Study
- ClinicalTrials.gov ID
- NCT07842861
- Acronym / sponsor ID
- MS-660-2025
- Conditions
- Morphine, Dexmedetomidine, Adjuvants, Bupivacaine, Transversus Abdominis Plane Block, Lower Abdominal Surgeries
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 70 participants (actual)
- Lead sponsor
- Cairo UniversityUniversity, hospital or other
- Study start
- 1 Dec 2025 (actual)
- Primary completion
- 1 Jun 2026 (actual)
- Study completion
- 1 Jun 2026 (actual)
- First posted
- 25 Sep 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study aimed to ascertain the safety and efficacy of dexmedetomidine in comparison to morphine as adjuvants to bupivacaine during transversus abdominis plane (TAP) block in postoperative pain management in adult patients undergoing lower abdominal surgery.
Detailed description
Postoperative pain is a significant contributor to higher morbidity, patient discomfort, and extended hospital stays.
The ultrasound-guided transversus abdominis plane (TAP) block has become more popular than systemic analgesics for reducing pain following abdominal surgery.
A plethora of adjuvants, including but not limited to morphine, fentanyl, and dexmedetomidine, have been incorporated into various regimens of TAP block, yielding disparate outcomes.
The use of alpha-2 agonist dexmedetomidine has been sanctioned for its application as an adjuvant in the management of pain and as a venous sedative.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Group D | Experimental | Drug: Transversus abdominis plane block + DexmedetomidinePatients received transversus abdominis plane (TAP) block with bupivacaine 0.25% plus a dose of 1 µg/kg of dexmedetomidine. |
| Group M | Experimental | Drug: MorphinePatients received a dose of 10 mg of morphine. |
Who may qualify
- Ages
- 18 to 60 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (5 listed)
- Age from 18 to 60 years.
- Both genders.
- Classified according to the American Society of Anesthesiologists physical status (ASA) classification system as I-II.
- Body mass index (BMI) of less than 30.
- Patients scheduled to undergo elective surgical procedures on the lower abdominal region.
Key exclusion criteria (6 listed)
- Patients with hypersensitivity to the utilized pharmaceutical agents.
- Mental disorders.
- Serious pulmonary or cardiac disease.
- Severe renal insufficiency.
- Coagulopathy.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Transversus abdominis plane block + DexmedetomidinePatients received transversus abdominis plane (TAP) block with bupivacaine 0.25% plus a dose of 1 µg/kg of dexmedetomidine. | Drug | Group D |
| MorphinePatients received a dose of 10 mg of morphine. | Drug | Group M |
Primary outcome
Duration of analgesia
Time frame: 24 hours postoperatively
Duration of analgesia was defined as the time interval from the end of the surgical procedure to the administration of the initial dose of morphine.
4 secondary outcomes
Total opioid dose required
Time frame: 24 hours postoperatively
Degree of pain
Time frame: 24 hours postoperatively
Incidence of adverse events
Time frame: 24 hours postoperatively
Degree of patient satisfaction
Time frame: 24 hours postoperatively
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 25 Sep 2026.
- Individual participant dataSharing planned: Yes. The data will be available upon a reasonable request from the corresponding author after the end of study for one year.
Related trials for Morphine
Recruiting
Comparison of Spinal Anesthesia With Intrathecal Morphine Versus PENG Block With or Without Dexamethasone in Hip Arthroplasty
Arthropathy of Hip, Hip Osteoarthritis
Recruiting
Tramadol Versus Morphine for Postoperative Pain Relief Following Laparoscopic Abdominal Surgery
Multimodal Analgesia, Tramadol
Recruiting
Lateral QL Block vs Intrathecal Morphine for Cesarean Section
Anesthesia, Postoperative Pain
Active, not recruitingPhase 3
An Extension Study of Ublituximab in Participants With Relapsing Multiple Sclerosis
Relapsing Multiple Sclerosis (RMS)
RecruitingObservational study
A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)
Relapsing Multiple Sclerosis, Multiple Sclerosis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Transversus abdominis plane block + Dexmedetomidine and Morphine in people with Morphine and Dexmedetomidine, run by Cairo University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 25 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Duration of analgesia (time frame: 24 hours postoperatively). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Sep 2026.